Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence

Malagoli, Piergiorgio;Dapavo, Paolo;Amerio, Paolo;Atzori, Laura

Co-primo

Writing – Review & Editing

;Balato, Anna;Bardazzi, Federico;Bianchi, Luca;Cattaneo, Angelo;Chiricozzi, Andrea;Congedo, Maurizio;Fargnoli, Maria Concetta;Giofrè, Claudia;Gisondi, Paolo;Guarneri, Claudio;Lembo, Serena;Loconsole, Francesco;Mazzocchetti, Giampiero;Mercuri, Santo Raffaele;Morrone, Pietro;Offidani, Anna Maria;Palazzo, Giovanni;Parodi, Aurora;Pellacani, Giovanni;Piaserico, Stefano;Potenza, Concetta;Prignano, Francesca;Romanelli, Marco;Savoia, Paola;Stingeni, Luca;Travaglini, Massimo;Trovato, Emanuele;Venturini, Marina;Zichichi, Leonardo;Costanzo, Antonio

2024-01-01

---

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.